Marketing Applications Continue To Fall In Canada, But MEDEC Expects Recovery Ahead
Executive Summary
Health Canada has reported a drop in medical device submissions, but medical technology industry group MEDEC is not expecting the decline to continue in the long term.
You may also be interested in...
Canadian Medtech Keeps An Eye On Transition To MDSAP; Regulator Won't Allow Grace Period
As Health Canada prepares to kick-start in 2017 its two-year plan to fully adopt the Medical Device Single Audit Program (MDSAP) in place of the current Canadian Medical Devices Conformity Assessment System (CMDCAS), the local medtech industry association MEDEC is upbeat about the change and says that while the transition plan may pose challenges, it believes it is too early to say what these might be1,2.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.